Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Figs Inc (FIGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Figs Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.60B), while Figs Inc trades at $14.15 (market cap $2.37B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 12.5× Figs Inc's market cap, and Figs Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | FIGS | |
|---|---|---|
Market Cap | $29.60B | $2.37B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $17.12 |
52-Week Low | $205.48 | $6.57 |
Enterprise Value | $27.56B | $2.13B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
FIGS stock trades at $14.50, up 0.76% today, with strong technical momentum and bullish moving averages. Recent Q2 2026 earnings beat expectations with $0.11 EPS and 29% revenue growth, leading to a raised 2026 outlook. The company maintains a high gross margin of 68.91% but faces valuation concerns with a P/E of 43.24. Analyst sentiment is positive with a $19.50 consensus price target.
Outlook remains favorable due to accelerating revenue growth and margin expansion, though the rich valuation and execution risks in H2 2026 pose challenges. Institutional buying and a $100 million share buyback program support bullish sentiment, but investors should weigh premium multiples against growth sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Figs Inc
FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle, and moisture-wicking properties.
Read more on FIGS →
